Soligenix Advances Rare Disease Therapies Amid Growing Healthcare Challenge.

Soligenix Inc. is developing treatments for rare diseases, including HyBryte for cutaneous T-cell lymphoma. The company is running a final confirmatory trial before seeking global marketing authorization. The NIH estimates over 30 million people in the US have a rare disease, with most having no FDA-approved therapies. Age-related changes can mask or delay diagnosis, making novel treatments crucial.